In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Protective effect of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in spontaneous hypertensive rats

Session Poster Session 6

Speaker Ting Tse Lin

Event : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : TTL Lin (Hsinchu,TW), YLS Sung (Hsinchu,TW), JYS Syu (Hsinchu,TW), HJH Hsu (Hsinchu,TW), KYL Lin (Hsinchu,TW), SFL Lin (Hsinchu,TW)

T.T.L. Lin1 , Y.L.S. Sung2 , J.Y.S. Syu2 , H.J.H. Hsu2 , K.Y.L. Lin2 , S.F.L. Lin1 , 1National Taiwan University Hospital Hsin-Chu Branch, Internal Medicine - Hsinchu - Taiwan , 2National Chiao Tung University - Hsinchu City - Taiwan ,

European Heart Journal ( 2019 ) 40 ( Supplement ), 3323

Background: Angiotensin-neprilysin inhibition compared to angiotensin inhibition decreased sudden cardiac death in patients with reduced ejection fraction heart failure. The protective effect from ventricular arrhythmia in diastolic heart failure (DHF) remains unknown.

Methods: The spontaneous hypertensive rat (SHR) has been well established as a suitable model for studies of DHF. A total of 18 10-week-old male SHR were divided into three groups: sacubitril/valsartan, valsartan and saline (0.9%) (n=6 in each group). Eighteen 10-week-old male Wistar-Kyoto rats (WKY) were served as the control group. After two weeks feeding with sacubitril/valsartan, valsartan and saline in SHR and WKY. Optical mapping was performed to measure the electrical dynamic of cardiac ventricle and the maximal slope of action potential duration restitution was calculated. An S1–S2 pacing protocol was applied at the right ventricle to determine inducibility of ventricular tachycardia and fibrillation (VT/VF).

Results: SHR revealed increased LV mass than those treated with sacubitril/valsartan, and valsartan. Compared with WKY, SHR had significantly higher max slope (1.32±0.12 vs. 0.28±0.08, p<0.001). SHR was less prone to arrhythmogenicity after treated with valsartan than saline (0.29±0.04 vs. 1.32±0.12, p<0.001). Furthermore, the max slope was even lower in SHR treated with sacubitril/valsartan than those with valsartan (0.10±0.03 vs. 0.29±0.04, p=0.005). The incidence of induced sustained VT/VF (duration >2 second) was significant higher in SHR compared with WKY (18±11.1% vs. 0%, p<0.001) and also higher in SHR treated with valsartan compared with those with sacubitril/valsartan (7±6.5% vs. 5±2.9%, p=0.036).

Conclusions: Angiotensin-neprilysin inhibition could provide better protection from ventricular arrhythmia than valsartan in SHR, warranting the further investigation of angiotensin-neprilysin inhibition in DHF patients.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are